Complement activation by C-reactive protein on the HEp-2 cell substrate.
The complement (C) activation by C-reactive protein (CRP) in acute-phase sera is routinely tested in our laboratory by means of an indirect immunofluorescence method (C3-IFT) on rat kidney sections. This C3-IFT assay is based on the binding of CRP to the renal tissue followed by the fixation of C4 and C3 components to distinct vessel-associated medullary structures as a result of CRP-mediated C activation in vitro. While the activation cascade leading to the deposition of C4 and C3 could previously be deduced experimentally, we were unable as yet to visualize CRP and the components of the C1 complex on kidney sections when testing patients' sera by indirect immunofluorescence. In an attempt to analyze the mechanisms of unexpectedly negative C3-IFT results (e.g. bacterial endocarditis) we employed monolayers of fixed HEp-2 cells which have previously been shown to be a suitable substrate for CRP binding. By incubating purified native CRP supplemented with normal human serum as a source of C we detected the C components Clq, Clr, Cls, C4 and C3 in the same speckled immunofluorescent pattern on HEp-2 cell nuclei as described characteristically for CRP binding. The serial activation steps from CRP up to C3 could also be followed on HEp-2 cells using C3-IFT-positive acute-phase sera. However, certain C3-IFT-negative acute-phase sera showed an arrest between Cls and C4 of the CRP-mediated C activation cascade. HEp-2 cells can thus be used to monitor the process of autologous C activation initiated by endogeneous CRP in patients' sera. In contrast to native CRP, urea-modified CRP (mCRP) did not bind to HEp-2 cell nuclei, but was detected in association with distinct filamentous cytoplasmic structures. Unlike its native counterpart, binding of mCRP was not followed by a deposition of C components.
Vaith
P
P
Department of Rheumatology and Clinical Immunology, Freiburg, Germany.
Prasauskas
V
V
Potempa
L A
LA
Peter
H H
HH
D000818:Animals; D002097:C-Reactive Protein / Q000037:antagonists & inhibitors / Q000276:immunology / Q000494:pharmacology*; D002478:Cells, Cultured; D003167:Complement Activation; D015922:Complement C1q / Q000378:metabolism; D015923:Complement C1r / Q000378:metabolism; D003173:Complement C1s / Q000378:metabolism; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D003171:Complement Pathway, Classical; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007668:Kidney / Q000166:cytology; D010767:Phosphorylcholine / Q000494:pharmacology; D051381:Rats; D012699:Serology
D003176:Complement C3; D003181:Complement C4; D010767:Phosphorylcholine; D015922:Complement C1q; D002097:C-Reactive Protein; D015923:Complement C1r; D003173:Complement C1s